GVR Report cover Cancer Vaccine Market Size, Share & Trends Report

Cancer Vaccine Market Size, Share & Trends Analysis Report By Vaccine Type (Preventive and Therapeutic), By Indication Type (Prostate Cancer, Breast Cancer), By Technology Type, By End-user, By Region, And Segment Forecasts, 2023 To 2030

  • Report ID: GVR454562
  • Number of Pages: 0
  • Format: Electronic (PDF)

Cancer vaccines are a type of immunotherapy that stimulates the immune system to recognize and attack malignant/tumorous cells. Increasing focus on personalized vaccines is among the key trend in the space. Personalized cancer vaccines are designed to target the unique genetic mutations found in an individual patient's tumor, making them more effective than traditional, one-size-fits-all oncology treatments. Several companies are developing these products, such as Genocea Biosciences and Moderna.

Advancement in vaccine technology is further driving the market growth. For instance, new delivery methods, such as nanoparticles and liposomes, are being developed to improve the efficacy of vaccines. Additionally, new adjuvants, which are substances that enhance the

immune response to a vaccine, are being explored to increase the overall effectiveness.

Moreover, government initiatives is one the prime factor that boost the overall cancer vaccines market. For instance, in January 2023, The UK government established a partnership with BioNTech for the development novel mRNA cancer vaccines. By 2030, this strategic collaboration aims to deliver approximately 10,000 personalized therapies to UK patients.

The market is segmented into vaccine type, indication type, and technological type. Based on vaccine type, the market is further differentiated into preventive vaccine and therapeutic vaccines. Among all the subsegments preventive vaccine dominate the market. Preventive Cancer vaccines have been shown to be highly effective in preventing certain types of tumor disease. For instance, the HPV vaccine has been shown to be highly effective in preventing cervical cancers caused by the targeted HPV types.

North America dominated the cancer vaccines market in 2022. North America is home to many of the world's leading pharmaceutical and biotech companies that invest heavily in research and development. This investment has resulted in the development of innovative vaccines that have been successful in treating a variety of oncology disorders. Moreover, North America is expected to grow due to the high prevalence of cancer. For instance, almost 1.9 million new cases of cancer are anticipated to be diagnosed in the U. S. in 2022, according to a report by the American Cancer Society. Moreover, 57% of patients in the United States are 65 or older, and 80% of patients in that country are adults aged 55 or older.

Cancer Vaccines Market Segmentation



Vaccine Type

Preventive Cancer Vaccines, Therapeutic Cancer Vaccines

Indication Type

Prostate cancer, Cervical Cancer, Other

Technology Type

Recombinant Cancer Vaccines, Whole-cell Cancer Vaccines, Viral Vector and DNA Cancer Vaccines, Other Technologies


The market is highly competitive and includes several key players. Some of the major companies operating in the marketplace include Merck & Co., Inc., GlaxoSmithKline plc, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca plc, Dendreon Pharmaceuticals LLC., Dynavax Technologies Corporation.

Companies are focusing on expansion of their product portfolio to meet the market demand as well as to be the key player in such a competitive marketplace. For instance, in November 2021, Shoreline Biosciences and Dendreon Pharmaceuticals launch CMC (Chemistry, Manufacturing and Controls) and manufacturing collaboration to strengthen the future of iPSC. With this expansion, both companies are focus on developing allogeneic, targeted natural killer (NK) and macrophage cellular immunotherapies for cancer 

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon